• Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. 

  Parker, CC; James, ND; Brawley, CD; Clarke, NW; Hoyle, AP; Ali, A; Ritchie, AWS; Attard, G; Chowdhury, S; Cross, W; Dearnaley, DP; Gillessen, S; Gilson, C; Jones, RJ; Langley, RE; Malik, ZI; Mason, MD; Matheson, D; Millman, R; Russell, JM; Thalmann, GN; Amos, CL; Alonzi, R; Bahl, A; Birtle, A; Din, O; Douis, H; Eswar, C; Gale, J; Gannon, MR; Jonnada, S; Khaksar, S; Lester, JF; O'Sullivan, JM; Parikh, OA; Pedley, ID; Pudney, DM; Sheehan, DJ; Srihari, NN; Tran, ATH; Parmar, MKB; Sydes, MR; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators (2018-12-01)

  BACKGROUND: Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low ...
• Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy. 

  Pathmanathan, AU; McNair, HA; Schmidt, MA; Brand, DH; Delacroix, L; Eccles, CL; Gordon, A; Herbert, T; van As, NJ; Huddart, RA; Tree, AC (2019-01-24)

  OBJECTIVE:: With increasing incorporation of MRI in radiotherapy, we investigate two MRI sequences for prostate delineation in radiographer-led image guidance. METHODS:: Five therapeutic radiographers contoured the prostate ...
• 'Relationship between thermal dose and cell death for "rapid" ablative and "slow" hyperthermic heating'. 

  Mouratidis, PXE; Rivens, I; Civale, J; Symonds-Tayler, R; Ter Haar, G (2019-01-31)

  AIM: Thermal isoeffective dose (TID) has not been convincingly validated for application to predict biological effects from rapid thermal ablation (e.g., using >55 °C). This study compares the classical method of quantifying ...
• Trans-abdominal in vivo placental vessel occlusion using High Intensity Focused Ultrasound. 

  Shaw, CJ; Rivens, I; Civale, J; Botting, KJ; Ter Haar, G; Giussani, DA; Lees, CC (2018-09-11)

  Pre-clinically, High Intensity Focused Ultrasound (HIFU) has been shown to safely and effectively occlude placental blood vessels in the acute setting, when applied through the uterus. However, further development of the ...
• Synthesis of a benzoxazinthione derivative of tanaproget and pharmacological evaluation for PET imaging of PR expression 

  Allott, L; Miranda, C; Hayes, A; Raynaud, F; Cawthorne, C; Smith, G (Springer Nature, 2019-12)
• Quantitative photoacoustic imaging study of tumours in vivo: Baseline variations in quantitative measurements. 

  Martinho Costa, M; Shah, A; Rivens, I; Box, C; O'Shea, T; Papaevangelou, E; Bamber, J; Ter Haar, G (2019-03)

  Photoacoustic imaging (PAI) provides information on haemoglobin levels and blood oxygenation (sO2). To facilitate assessment of the variability in sO2 and haemoglobin in tumours, for example in response to therapies, the ...
• APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. 

  Huff, AL; Wongthida, P; Kottke, T; Thompson, JM; Driscoll, CB; Schuelke, M; Shim, KG; Harris, RS; Molan, A; Pulido, JS; Selby, PJ; Harrington, KJ; Melcher, A; Evgin, L; Vile, RG (2018-12-21)

  Tumor cells frequently evade applied therapies through the accumulation of genomic mutations and rapid evolution. In the case of oncolytic virotherapy, understanding the mechanisms by which cancer cells develop resistance ...
• The Intracranial Distribution of Gliomas in Relation to Exposure From Mobile Phones: Analyses From the INTERPHONE Study. 

  Grell, K; Frederiksen, K; Schüz, J; Cardis, E; Armstrong, B; Siemiatycki, J; Krewski, DR; McBride, ML; Johansen, C; Auvinen, A; Hours, M; Blettner, M; Sadetzki, S; Lagorio, S; Yamaguchi, N; Woodward, A; Tynes, T; Feychting, M; Fleming, SJ; Swerdlow, AJ; Andersen, PK (2016-12-01)

  When investigating the association between brain tumors and use of mobile telephones, accurate data on tumor position are essential, due to the highly localized absorption of energy in the human brain from the radio-frequency ...
• Repression of Transcription at DNA Breaks Requires Cohesin throughout Interphase and Prevents Genome Instability. 

  Meisenberg, C; Pinder, SI; Hopkins, SR; Wooller, SK; Benstead-Hume, G; Pearl, FMG; Jeggo, PA; Downs, JA (2019-01-17)

  Cohesin subunits are frequently mutated in cancer, but how they function as tumor suppressors is unknown. Cohesin mediates sister chromatid cohesion, but this is not always perturbed in cancer cells. Here, we identify a ...
• Cell-type-specific eQTL of primary melanocytes facilitates identification of melanoma susceptibility genes. 

  Zhang, T; Choi, J; Kovacs, MA; Shi, J; Xu, M; NISC Comparative Sequencing Program; Melanoma Meta-Analysis Consortium; Goldstein, AM; Trower, AJ; Bishop, DT; Iles, MM; Duffy, DL; MacGregor, S; Amundadottir, LT; Law, MH; Loftus, SK; Pavan, WJ; Brown, KM (2018-11)

  Most expression quantitative trait locus (eQTL) studies to date have been performed in heterogeneous tissues as opposed to specific cell types. To better understand the cell-type-specific regulatory landscape of human ...
• A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. 

  Lu, Y; Beeghly-Fadiel, A; Wu, L; Guo, X; Li, B; Schildkraut, JM; Im, HK; Chen, YA; Permuth, JB; Reid, BM; Teer, JK; Moysich, KB; Andrulis, IL; Anton-Culver, H; Arun, BK; Bandera, EV; Barkardottir, RB; Barnes, DR; Benitez, J; Bjorge, L; Brenton, J; Butzow, R; Caldes, T; Caligo, MA; Campbell, I; Chang-Claude, J; Claes, KBM; Couch, FJ; Cramer, DW; Daly, MB; deFazio, A; Dennis, J; Diez, O; Domchek, SM; Dörk, T; Easton, DF; Eccles, DM; Fasching, PA; Fortner, RT; Fountzilas, G; Friedman, E; Ganz, PA; Garber, J; Giles, GG; Godwin, AK; Goldgar, DE; Goodman, MT; Greene, MH; Gronwald, J; Hamann, U; Heitz, F; Hildebrandt, MAT; Høgdall, CK; Hollestelle, A; Hulick, PJ; Huntsman, DG; Imyanitov, EN; Isaacs, C; Jakubowska, A; James, P; Karlan, BY; Kelemen, LE; Kiemeney, LA; Kjaer, SK; Kwong, A; Le, ND; Leslie, G; Lesueur, F; Levine, DA; Mattiello, A; May, T; McGuffog, L; McNeish, IA; Merritt, MA; Modugno, F; Montagna, M; Neuhausen, SL; Nevanlinna, H; Nielsen, FC; Nikitina-Zake, L; Nussbaum, RL; Offit, K; Olah, E; Olopade, OI; Olson, SH; Olsson, H; Osorio, A; Park, SK; Parsons, MT; Peeters, PHM; Pejovic, T; Peterlongo, P; Phelan, CM; Pujana, MA; Ramus, SJ; Rennert, G; Risch, H; Rodriguez, GC; Rodríguez-Antona, C; Romieu, I; Rookus, MA; Rossing, MA; Rzepecka, IK; Sandler, DP; Schmutzler, RK; Setiawan, VW; Sharma, P; Sieh, W; Simard, J; Singer, CF; Song, H; Southey, MC; Spurdle, AB; Sutphen, R; Swerdlow, AJ; Teixeira, MR; Teo, SH; Thomassen, M; Tischkowitz, M; Toland, AE; Trichopoulou, A; Tung, N; Tworoger, SS; van Rensburg, EJ; Vanderstichele, A; Vega, A; Edwards, DV; Webb, PM; Weitzel, JN; Wentzensen, N; White, E; Wolk, A; Wu, AH; Yannoukakos, D; Zorn, KK; Gayther, SA; Antoniou, AC; Berchuck, A; Goode, EL; Chenevix-Trench, G; Sellers, TA; Pharoah, PDP; Zheng, W; Long, J (2018-09-15)

  Large-scale genome-wide association studies (GWAS) have identified approximately 35 loci associated with epithelial ovarian cancer (EOC) risk. The majority of GWAS-identified disease susceptibility variants are located in ...
• Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. 

  Bahig, H; Yuan, Y; Mohamed, ASR; Brock, KK; Ng, SP; Wang, J; Ding, Y; Hutcheson, K; McCulloch, M; Balter, PA; Lai, SY; Al-Mamgani, A; Sonke, J-J; van der Heide, UA; Nutting, C; Li, XA; Robbins, J; Awan, M; Karam, I; Newbold, K; Harrington, K; Oelfke, U; Bhide, S; Philippens, MEP; Terhaard, CHJ; McPartlin, AJ; Blanchard, P; Garden, AS; Rosenthal, DI; Gunn, GB; Phan, J; Cazoulat, G; Aristophanous, M; McSpadden, KK; Garcia, JA; van den Berg, CAT; Raaijmakers, CPJ; Kerkmeijer, L; Doornaert, P; Blinde, S; Frank, SJ; Fuller, CD (2018-11)

  Background: Current standard radiotherapy for oropharynx cancer (OPC) is associated with high rates of severe toxicities, shown to adversely impact patients' quality of life. Given excellent outcomes of human papilloma ...
• Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). 

  Marabelle, A; Andtbacka, R; Harrington, K; Melero, I; Leidner, R; de Baere, T; Robert, C; Ascierto, PA; Baurain, J-F; Imperiale, M; Rahimian, S; Tersago, D; Klumper, E; Hendriks, M; Kumar, R; Stern, M; Öhrling, K; Massacesi, C; Tchakov, I; Tse, A; Douillard, J-Y; Tabernero, J; Haanen, J; Brody, J (2018-11-01)

  A European Society for Medical Oncology (ESMO)-sponsored expert meeting was held in Paris on 8 March 2018 which comprised 11 experts from academia, 11 experts from the pharmaceutical industry and 2 clinicians who were ...
• Ultrahigh Dose-rate Radiotherapy: Next Steps for FLASH-RT. 

  Harrington, KJ (2019-01-01)

  A new way of delivering radiotherapy at very high dose rates is described and compared with conventional radiotherapy. The ultrahigh dose-rate therapy reduces damage to normal pig skin and exerts potent activity against ...
• Brain and Salivary Gland Tumors and Mobile Phone Use: Evaluating the Evidence from Various Epidemiological Study Designs. 

  Röösli, M; Lagorio, S; Schoemaker, MJ; Schüz, J; Feychting, M (2019-01-11)

  Mobile phones (MPs) are the most relevant source of radiofrequency electromagnetic field (RF-EMF) exposure to the brain and the salivary gland. Whether this exposure implies a cancer risk has been addressed in several ...
• Transcriptome-wide association study identifies new candidate susceptibility genes for glioma. 

  Atkins, I; Kinnersley, B; Ostrom, QT; Labreche, K; Il'yasova, D; Armstrong, GN; Eckel-Passow, JE; Schoemaker, MJ; Nöthen, MM; Barnholtz-Sloan, JS; Swerdlow, AJ; Simon, M; Rajaraman, P; Chanock, SJ; Shildkraut, J; Bernstein, JL; Hoffmann, P; Jöckel, K-H; Lai, RK; Claus, EB; Olson, SH; Johansen, C; Wrensch, MR; Melin, B; Jenkins, RB; Sanson, M; Bondy, ML; Houlston, RS (2019-02-01)

  Genome-wide association studies (GWAS) have so far identified 25 loci associated with glioma risk, with most showing specificity for either glioblastoma (GBM) or non-GBM tumors. The majority of these GWAS susceptibility ...
• Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy. 

  Bashir, U; Tree, A; Mayer, E; Levine, D; Parker, C; Dearnaley, D; Oyen, WJG (2019-01-08)

  PURPOSE: With the availability of ultra-sensitive PSA assays, early biochemical relapse (eBCR) of prostate cancer is increasingly being detected at values much lower than the conventional threshold of 0.2 ng/ml. Accurate ...
• Mendelian randomization: a powerful and inexpensive method for identifying and excluding non-genetic risk factors for colorectal cancer 

  Cornish, A; Houlston, R
• Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES. 

  Szijgyarto, Z; Flach, KD; Opdam, M; Palmieri, C; Linn, SC; Wesseling, J; Ali, S; Bliss, JM; Cheang, MCU; Zwart, W; Coombes, RC (2019-01-24)

  PURPOSE: The prognostic and predictive values of the MAPK/AKT/ERα phosphorylation axis (pT202/T204MAPK, pT308AKT, pS473AKT, pS118ERα and pS167ERα) in primary tumours were assessed to determine whether these markers can ...
• CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. 

  Gillison, ML; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, KJ; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Iglesias Docampo, LC; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Monga, M; Lynch, M; Li, L; Ferris, RL (2018-09)

  Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) ...

View more